Clinical trial · Interventional
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders
NCT00636909CI-TRIAL-00026828MINI HEMEcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects. We hope to decrease these side effects by decreasing the chemotherapy dose prior to transplant (non-myeloablative, smaller dose of chemotherapy given so bone marrow is not completely eliminated) and by using donated stem cells to treat cancer of the blood.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ALL | Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| AML | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| APLASTIC ANEMIA | — | UNRESOLVED | — |
| CLL | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| CML Chronic Phase, Accelerated Phase, or Blast Crisis | — | UNRESOLVED | — |
| MDS | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
| MULTIPLE MYELOMA | Multiple Myeloma | CURATED_EXACT | 0.92 |
| MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) | Myeloproliferative Neoplasm | ALIAS | 0.85 |
| RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| cyclosporine | Drug | — | UNRESOLVED |
| fludarabine | Drug | Fludarabine | ALIAS |
| G-CSF | Biological | — | UNRESOLVED |
| methotrexate | Drug | Methotrexate | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Study treatment arm with G-CSF
- interventionNames
- Drug: Cyclophosphamide
- Drug: fludarabine
- Drug: cyclosporine
- Drug: methotrexate
- Biological: G-CSF
Primary outcomes (3)
- measure
- durable engraftment
- timeFrame
- 100 days
- measure
- hematopoeitic reconstitution
- timeFrame
- 3 years
- measure
- evaluate the patterns of post-transplant chimerism among lymphoid and antigen presenting cells
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria - Patient: * AML, ALL,CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL, MDS, RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA, Aplastic Anemia, Multiple Myeloma, MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET * Age less than 65 years * Patients must have a healthy family member who is HLA-identical to the recipient or has 1 antigen mismatch and who is willing to receive a course of G-CSF and undergo 2-4 daily leukaphereses * Each patient must sign an informed consent and be willing to participate as a research subject after having been advised of the nature and risk of the study prior to entering protocol Inclusion Criteria - Donor: * Absence of hematologic or marrow function related diseases that interferes with the collection of sufficient numbers of normal progenitor cells * Absence of any medical condition that would pose a serious health risk by undergoing peripheral blood stem cell harvest * Negative HIV, HTLV-1, Hepatitis B surface antigen and Hepatitis C * The donor must be blood relation. A prospective related donor must be at least genotypically HLA-A, B, DR identical to the patient, but can differ for 1 HLA-locus. Exclusion Criteria - Patient: * Active CNS involvement * Females who are pregnant or breast feeding * ECOG performance status \> 1. Karnofsky performance status \< 80% * LVEF \< 40% * Active viral, bacterial, or fungal infection * Patients seropositive for HIV; HTLV -1 * Patients not providing informed consent * Patients with known hypersensitivity to E. Coli derived product Exclusion Criteria - Donor: * A positive HIv infection or HTLV - 1 test or evidence of active/persistent viral hepatitis infection. Presence of any medical condition that would pose a serious health risk by undergoing peripheral blood stem cell harvest. Donors with known hypersensitivity to E. Coli derived products.
References
Publications (0)
Data not yet available
No reference posted for this study.